This publication does not argue against an ambitious agenda for change. On the contrary, Australia's decision-making on health technologies is crying out for change. The argument is that it cannot be delivered within the constraints of an institution that has never demonstrated any ability to reform itself, engage in self-reflection, or take responsibility for the issues afflicting access in Australia.
Be clear-eyed about whatever trade-offs the institution demands you accept
September 10, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News

